About JC Muyl
JC Muyl is the founder of MyRareData, dedicated to helping rare disease patients navigate challenges through digital tools. He brings over four decades of digital health expertise with recent focus on rare diseases. Originally from Europe, JC has spent his career in the U.S., transitioning from startup operations to mentoring.
His professional background includes growing a 30-person startup into a 1,400-employee global healthcare organization and launching multiple business lines across diverse healthcare segments. Beyond work, he actively volunteers for mental and physical disability causes and remains committed to delivering financially sustainable digital health solutions for rare disease communities.
Key Challenges of Rare Disease
The low prevalence of rare diseases -- typically affecting fewer than 200,000 people in the U.S. -- systematically disadvantages affected families. Patients often face years of diagnostic "odysseys," visiting numerous doctors seeking definitive answers. Due to scarcity of specialized medical professionals, families frequently become experts on their own conditions while navigating limited treatment options.
The Power of Online Communities
Online communities have become invaluable for the rare disease world, particularly since the pandemic made physical meetings difficult. As JC notes, patients in these communities "are deeply willing to share, help others, and bring people together -- even when the system is not welcoming to their challenges." While building these communities requires patience, their long-term impact is significant for rare disease advocacy.
AI's Potential in Rare Disease Care
AI offers promising applications including literature review and drug repurposing by analyzing datasets to identify existing medications for rare diseases. Agentic AI can assist with administrative tasks like reimbursement fights and travel organization.
However, implementation requires addressing authenticity of sources, data privacy, patient consent, and equitable monetization to build necessary trust. The path forward requires balancing technological innovation with the deeply human needs of rare disease communities.